# The Cooper Companies, Inc. (COO) Stock Analysis: Exploring a 25.83% Potential Upside

- Link: https://www.directorstalkinterviews.com/the-cooper-companies-inc-coo-stock-analysis-exploring-a-25-83-potential-upside/4121214360
- Published: 2025-09-01T10:24:05+01:00
- Author: Madison Wilson

The Cooper Companies, Inc. (NYSE: COO), a key player in the healthcare sector, specifically
within the medical instruments and supplies industry, is drawing attention from 
investors with its promising growth trajectory. Headquartered in San Ramon, California,
Cooper Companies operates through two main segments: CooperVision and CooperSurgical.
These divisions focus on advancing vision correction solutions and women’s health
care products, respectively, addressing a broad spectrum of consumer and professional
needs across the globe.

With a market capitalization of $13.4 billion, Cooper Companies holds a significant
position in the healthcare landscape. Its current share price stands at $67.395,
with a modest price change of 0.04% recently. This valuation places the company 
at the lower end of its 52-week range, which spans from $64.58 to $111.23, indicating
potential room for recovery and growth.

Analysts have taken note of this potential. With 11 buy ratings and 6 hold ratings,
the sentiment leans toward optimism, as there are no sell ratings in sight. The 
average target price is pegged at $84.80, suggesting a potential upside of 25.83%
from current levels. This attractive target range of $66.00 to $96.00 underscores
the confidence the market has in Cooper Companies’ strategic direction and growth
prospects.

Despite the absence of a trailing P/E ratio and other traditional valuation metrics
like the PEG ratio and price/book ratio, the forward P/E of 15.25 offers a glimpse
into future earnings expectations. The company’s revenue growth rate of 5.70% and
an EPS of 2.04 illustrate a steady, albeit not explosive, growth trajectory. Furthermore,
a return on equity of 5.01% and a substantial free cash flow of over $276 million
underscore the company’s ability to generate cash and sustain operations without
relying heavily on external financing.

From a technical perspective, Cooper Companies is currently trading below both its
50-day and 200-day moving averages, which stand at $72.22 and $83.42, respectively.
This positioning, coupled with an RSI of 68.44, suggests the stock is nearing overbought
territory, hinting at potential short-term price corrections. However, long-term
investors might view this as an opportunity to capitalize on potential upside as
the company navigates its market challenges.

The absence of a dividend yield and a payout ratio of 0.00% indicate that Cooper
Companies is reinvesting its earnings back into the business, potentially driving
further innovation and growth. This strategy aligns with the company’s focus on 
expanding its product offerings and market reach, particularly in the fields of 
contact lenses and women’s healthcare solutions.

Overall, Cooper Companies presents a compelling case for investors seeking exposure
to the healthcare sector. With a diversified product portfolio and a strong presence
in both vision care and women’s health, the company is well-positioned to capitalize
on global healthcare trends. Investors should keep an eye on Cooper Companies as
it continues to leverage its expertise and capitalize on growth opportunities in
the evolving healthcare market.

Share on:
